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ARTICLE
Immuno-detection by sequencing enables large-
scale high-dimensional phenotyping in cells
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Jesse Middelwijk4, Ruud van der Steen4, Michiel Vermeulen3, Hendrik G. Stunnenberg3,
Cornelis A. Albers1,2 & Klaas W. Mulder1
Cell-based small molecule screening is an effective strategy leading to new medicines. Sci-
entists in the pharmaceutical industry as well as in academia have made tremendous pro-
gress in developing both large-scale and smaller-scale screening assays. However, an
accessible and universal technology for measuring large numbers of molecular and cellular
phenotypes in many samples in parallel is not available. Here we present the immuno-
detection by sequencing (ID-seq) technology that combines antibody-based protein detec-
tion and DNA-sequencing via DNA-tagged antibodies. We use ID-seq to simultaneously
measure 70 (phospho-)proteins in primary human epidermal stem cells to screen the effects
of ~300 kinase inhibitor probes to characterise the role of 225 kinases. The results show an
association between decreased mTOR signalling and increased differentiation and uncover 13
kinases potentially regulating epidermal renewal through distinct mechanisms. Taken toge-
ther, our work establishes ID-seq as a ﬂexible solution for large-scale high-dimensional
phenotyping in ﬁxed cell populations.
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Quantiﬁcation of protein levels and phosphorylation eventsis central to investigating the cellular response to per-turbations such as drug treatment or genetic defects. This
is particularly important for cell-based phenotypic screens to
discover novel drug leads in the pharmaceutical industry. How-
ever, the complexity of biological and disease processes is not
easily captured by changes in individual markers. Currently, a
major limitation is the trade-off between the number of samples
and the number of (phospho-)proteins that can be measured in a
single experiment. For instance, immunohistochemistry (IHC)1
and immunoﬂuorescence (IF)2 allow high-throughput protein
measurements using ﬂuorescently labelled antibodies. However,
these methods are limited in the number of (phospho-)proteins
that can be measured simultaneously in each sample due to
spectral overlap of the ﬂuorescent reporter dyes. One commercial
solution, Luminex®, has circumvented this limitation by using
colour-barcoded antibody-loaded beads and allows multiplexing
of some 50 proteins per sample3–5. However, this approach
requires cell lysis and does currently not include phospho-speciﬁc
signalling detection. Several alternative approaches based on
antibody–DNA conjugates have been developed in recent
years6, 7. For instance, Ullal et al. used the Nanostring system to
quantify 88 antibody–single-strand DNA (ssDNA) oligo con-
jugates in ﬁne needle aspirates6. Although powerful, this strategy
is not well suited for high-throughput applications. Furthermore,
the commercial Proseek® strategy entails a proximity extension
assay using pairs of ssDNA oligo coupled antibodies in combi-
nation with quantitative PCR as a read-out7. This assay is gen-
erally performed on cell lysates and currently there are no assays
for phospho-proteins available to study signalling activity. In
addition, several other recently described antibody– DNA
conjugate-based methods that use high-throughput sequencing as
a read-out detect only a few extracellular epitopes or at low
sample throughput8–12, limiting their scope. Here we present
immuno-detection by sequencing (ID-seq) as a streamlined uni-
versal technology for measuring large numbers of molecular
phenotypes, for many samples in parallel. We show that high-
throughput sequencing of antibody-coupled DNA barcodes
allows accurate and reproducible quantiﬁcation of 84 (phospho-)
proteins in hundreds of samples simultaneously. We apply ID-seq
in conjunction with the published kinase inhibitor set (PKIS) to
start investigating the role of >200 kinases in primary human
epidermal stem cell renewal and differentiation. This demon-
strates a downregulation of mammalian target-of-rapamycin
(mTOR) signalling during differentiation and uncoveres 13
kinases potentially regulating epidermal renewal through distinct
mechanisms.
Results
Precise and sensitive (phospho-)protein detection. We designed
the ID-seq technology to simultaneously measure many proteins
and post-translational modiﬁcations in high-throughput (Fig. 1a).
At the basis of ID-seq lie antibodies that are labelled with a
double-stranded DNA (dsDNA) tag13 containing a 10-nucleotide
antibody-dedicated barcode and a 15-nucleotide unique mole-
cular identiﬁer (UMI, Supplementary Fig. 1, Supplementary
note 1). Each antibody signal is now digitised and non-over-
lapping, allowing many antibodies to be combined and measured
simultaneously. Following immunostaining and washing, DNA
barcodes are released from the antibodies through reduction of a
chemically cleavable linker13 and a sample-speciﬁc barcode is
added through PCR. Finally, samples are pooled to prepare an
indexed sequencing library (Fig. 1a, Supplementary Fig. 1 and
Supplementary note 1). This triple barcoding strategy facilitates
straightforward incorporation of hundreds (and potentially
thousands) of samples per experiment and achieves count-based
quantiﬁcation (Supplementary Fig. 2 and Supplementary note 2)
with a dynamic range of four orders of magnitude (Supplemen-
tary Fig. 3). Furthermore, analyses of 17 antibody–DNA con-
jugates using singleplex and multiplexed measurements show
high correspondence (R= 0.98 ± 0.046), demonstrating that
multiplexing does not interfere with antibody detection (Fig. 1b).
Moreover, the ID-seq library preparation procedure is repro-
ducible (R= 0.98, Fig. 1c) and precise, as determined using nine
distinct DNA tag sequences per antibody, serving as technical
replicates (R > 0.99, Supplementary Fig. 4). Finally, cell-dilution
series and small interfering RNA (siRNA)-mediated silencing of
selected proteins showed an epitope abundance-dependent
decrease of antibody-barcode counts, conﬁrming the speciﬁcity
of the ID-seq signals (Supplementary Fig. 5 a, b). Collectively,
these experiments show that the ID-seq technology allows precise,
sensitive and speciﬁc multiplexed protein quantiﬁcation through
sequencing antibody-coupled DNA tags.
Constructing a 70 antibody–DNA conjugate ID-seq panel. To
fully exploit the multiplexing capacity of ID-seq, we obtained 111
antibodies targeting intracellular and extracellular epitopes. We
aimed to generate an antibody panel that will allow us to deter-
mine the state of the cell in a broad manner and where possible
should be reactive towards both human and mouse epitopes.
Therefore, the initial selection of antibodies covered a wide range
of cellular processes, including cell cycle, DNA damage, epi-
dermal self-renewal and differentiation, as well as the intracellular
signalling status for the epidermal growth factor (EGF), G-
protein-coupled receptors, calcium signalling, tumour necrosis
factor-α (TNFα), transforming growth factor-β (TGFβ), Notch,
WNT and BMP pathways, and can potentially be applied to a
variety of cellular systems. All of the selected antibodies were
validated for speciﬁcity in IF, IHC and/or ﬂuorescence-activated
cell sorting applications by the vendor (see Supplementary Data 1
for details and links to datasheets). As these applications include
cell ﬁxation, we reasoned that this selection would increase the
chance of identifying antibodies that are suitable for ID-seq. From
these 111 antibodies, 84 showed sound signals in in-cell-western/
IF and/or immuno-PCR experiments using antibody dilutions
and/or IgG control antibodies (Supplementary Figs. 6 and 7). To
increase our conﬁdence in this set of antibodies, we performed a
series of experiments using IF, immuno-PCR and/or ID-seq as a
read-out to verify that the tested antibodies show the expected
signal dynamics in response to speciﬁc perturbations. These
perturbations included: induction of differentiation; stimulation
with EGF or bone morphogenetic proteins (BMPs); induction of
DNA damage signalling with mitomycin C or hydroxyurea, as
well as inhibition of EGF and BMP signalling with the small
molecule inhibitors AG1478 and DMH1, respectively (Supple-
mentary Fig. 8). Also, signals of a subset of phospho-speciﬁc
antibodies were decreased upon phosphatase treatment of ﬁxed
cell populations (Supplementary Fig. 9 and Supplementary
Data 1). Taken together, 64 out of the 84 antibodies exhibited the
expected protein or phospho-protein dynamics in our primary
skin stem cells in these experiments, whereas the rest was stable,
indicating their utility in ID-seq. The 84 antibodies displayed
~75-fold signal over no-cell background, a measure of technical
noise (Supplementary Fig. 10). Moreover, we found that the
variability of the signals from a subpanel of 69 antibody–DNA
conjugates was below 20% among 14 biological replicates (coef-
ﬁcient of variation < 0.2, Fig. 1d), demonstrating the precision
and reproducibility of highly multiplexed ID-seq measurements.
These experiments enabled us to construct a panel of ~70
antibody–DNA conjugates to evaluate protein levels and
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Fig. 1 Immuno-detection by sequencing (ID-seq) technology development. a Concept of the ID-seq technology. First, pool DNA-tagged antibodies. Second,
perform multiplexed immunostaining on ﬁxed cell populations, and release DNA tags. Third, barcode the released DNA tags through a two-step PCR
protocol. Finally, sequence the barcoded DNA tags via next-generation sequencing (NGS) and count barcodes. b Signals from singleplex epitope detection
(via an immuno-PCR measurement) were compared with multiplexed epitope detection using ID-seq. The histogram summarises correlations between 17
immuno-PCR and corresponding ID-seq measurements. Insert panel illustrates an example from the actin antibody showing signal mean and s.d. (n= 4).
Underlying data for all 17 antibodies can be found in Supplementary Fig. 4. c Scatterplot indicates the high reproducibility of PCR-based ID-seq library
preparation (r= Pearson correlation). Libraries from the same released material were prepared on separate occasions and analysed in different sequencing
runs. d The scatterplot shows the counts (mean) and coefﬁcient of variation from 69 antibody–DNA conjugates (n= 14 biological replicates). Dashed line
indicates 20% variation. e Volcano plot shows the effect (estimate) and signiﬁcance (−log10 pval) of AG1478 treatment (n= 6), based on the model
analysis of ID-seq counts (Supplementary Note 3). Signiﬁcance (−log10 pval) determines node size. Red nodes show signiﬁcantly increased (ANOVA, p <
0.01) and blue nodes show signiﬁcantly decreased (ANOVA, p < 0.01) (phosphor-)protein levels. f Pathway overview of ID-seq measurements after 48 h
of AG1478 treatment. Colour indicates the effect size and node size represents the signiﬁcance of effect (−log10 pval). Light grey nodes without border
indicate not measured (nm) proteins (see Supplementary Supplementary Fig. 12 for (phospho-)protein identities)
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intracellular signalling, covering a broad range of biological
processes, including cell cycle, apoptosis, DNA damage and cell-
type-speciﬁc epidermal self-renewal and differentiation. Also, the
panel covers intracellular signalling pathways EGF, G-protein-
coupled receptors, calcium signalling, TNFα, TGFβ, NOTCH,
BMP and WNT pathways (Supplementary Data 1). Of note, the
nature of the selected and validated antibodies should make this
panel broadly applicable to many other human (and mouse)-
derived cell systems, and other antibodies can be added when
required.
Measuring (phospho-)protein levels in human skin stem cells.
Primary human epidermal stem cells (keratinocytes) depend on
active EGF receptor (EGFR) signalling for self-renewal in vitro
and vivo14. We inhibited this pathway using the potent and
selective inhibitor AG1478 at a concentration suitable for cell-
based assays (10 μM, 48 h) to determine whether ID-seq recapi-
tulates keratinocyte biology. In these experiments, we would
expect to at least observe dynamic changes in downstream EGFR
signalling pathway activity, as well as in the expression of
differentiation-associated proteins. To analyse the effects of
AG1478 treatment on each antibody signal, we developed a
generalised linear mixed (glm) model that takes into account the
negative binomial distribution of ID-seq count data and
incorporates potential sources of variation (e.g., replicates, bat-
ches and sequencing depth). This model derives the effect
(‘estimate’) of treatment on each antibody, followed by a like-
lihood ratio test to determine the signiﬁcance of the effect
(Supplementary note 3). We identiﬁed 13 increased and 7
decreased (phospho-)proteins upon AG1478 treatment (p < 0.01,
analysis of variance, Fig. 1e). Upregulation of the known differ-
entiation markers transglutaminase 1 (TGM1) and NOTCH1
conﬁrmed successful differentiation. Although the induction of
late differentiation marker TGM1 was relatively modest at this
early stage of differentiation (48 h of EGFR inhibition), quanti-
tative proteomics, IF and quantitative reverse transcription PCR
(RT-qPCR) measurements showed comparable increases of
TGM1 levels (Supplementary Fig. 11). This indicates that modest,
yet biologically informative, effects can be identiﬁed using the
ID-seq technology.
Next, we projected the estimates and signiﬁcance levels of our
ID-seq results onto a literature-derived signalling network (Fig. 1f,
see Supplementary Fig. 12a for node identities). As expected,
EGFR pathway activity was downregulated upon AG1478
treatment. We also identiﬁed effects on the activity of several
other pathways, including the BMP and Notch cascades, which
are known players in epidermal biology15–18. RT-qPCR analysis
revealed that these effects arose from changes in mRNA
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Fig. 2 ID-seq screen of PKIS identiﬁes probes inducing skin stem cell differentiation. a Schematic overview of the protein kinase inhibitor set (PKIS) screen
set-up. Kinase tree shows kinases targeted by the inhibitory probes (blue) and signiﬁcantly enriched kinases (yellow, Fig. 4a). The probes target all major
kinase families (TKL, STE, CK, AGC, CAMK, CMGC and TK). b To combine PKIS probe effects on multiple ID-seq molecular phenotypes to one measure,
we performed principal component analysis on the PKIS data set using the signed log10 p-values of the ID-seq analysis. Then, we clustered all molecular
phenotypes and the top ﬁve PCs to identify the PC summarising differentiation of the skin stem cells (in bold molecular phenotypes TGM1 and NOTCH1). c
ID-seq measurement of differentiation marker TGM1, Notch 1, GAPDH, Cyclin B1 and SMAD3 upon inhibition of EGFR shows differentiation-induced
phenotypic changes. (Boxplots with centre line indicating median, bounds of boxes showing upper and lower quartile, and whiskers illustrating 1.5 ×
interquartile range, n= 6)
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expression of BMP ligands and NOTCH receptors (Supplemen-
tary Fig. 12b). We conﬁrmed activation of the BMP and Notch
pathways by RT-qPCR analysis of their classical downstream
target genes ID2 and HES2, respectively (Supplementary Fig. 12b).
These results demonstrate the potential of ID-seq and our glm
model to distinguish different treatment conditions by quantify-
ing changes in (phospho-)protein dynamics.
Kinase inhibitors induce skin stem cell differentiation. As we
are able to interrogate the complex biological process of kerati-
nocyte differentiation underlying EGFR, we decided to expand
our search. Extracellular signals involved in epidermal renewal
and differentiation are widely studied and include EGF, TGFβ,
BMP, Notch ligands and Wnts15, 19–23. However, the contribu-
tions of different intracellular effector kinases on renewal and
differentiation are not well documented. To start addressing this
issue, we applied ID-seq to human epidermal keratinocytes
treated with the PKIS, an open-source chemical probe library24–26
containing ~300 small molecules targeting 225 kinases across all
major kinase families in the human proteome (Fig. 2a). To
determine the effects of kinase inhibition at the molecular level,
we performed ID-seq with a panel of 70 antibodies on cells seeded
in 384-well plates and treated with 294 PKIS compounds for
24 h. Replicate screens were highly correlated (R= 0.98) and had
low UMI duplicate rates (1.2%), indicating high data quality
(Supplementary Fig. 13a-e). We annotated the effect and its
signiﬁcance for each kinase inhibitor probe on each of the mea-
sured molecular phenotypes (as measured by our antibody con-
jugates) and used the results of this analysis to interrogate the
effect of kinase inhibition on skin stem cell biology.
A key advantage of the high multiplexing capacity of ID-seq is
its potential to simultaneously measure multiple antibodies
reﬂecting a given biological process. We anticipate this to result
in a more reliable and comprehensive measurement of the
affected processes compared to quantiﬁcation of a single marker.
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Fig. 3 Probes with high PC2 affect differentiation, cell-cycle arrest and mTOR signalling activity. a Summary of signiﬁcantly (p < 0.01, FDR 1%, t-test,
Supplementary Fig. 17) affected molecular phenotypes from probes with high PC2 (top 10%) compared to low PC2 (bottom 10%). b Scatterplot illustrating
probes with high PC2 score (x-axis) have increased TGM1 and NOTCH1 levels measured by ID-seq. c Scatterplot illustrating probes with high PC2 score
(x-axis) have increased cell-cycle arrest marker (Cyclin B1 and p-cdc2) levels measured by ID-seq. d Scatterplot showing the probes with high PC2 score
(x-axis) strongly have decreased phospho-S6 and phospho-mTOR levels illustrating decreased mTOR signalling activity measured by ID-seq
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We exploited the multiplexed nature of the ID-seq data by
combining the individual phenotypic ID-seq measurements into
principal components (PCs) through PC analysis (PCA). The
PCA essentially aggregates the molecular phenotypes that jointly
explain independent fractions of variation in the data into a single
score, which in turn represents the effect of the inhibitory probes
on the skin stem cells. To determine the underlying processes
associated with each PC per probe, we correlated and clustered
the measured antibodies with the top four PCs explaining 38% of
total variation in the data set (Fig. 2b, Supplementary Fig. 14). As
expected from a screen using kinase inhibitor probes a
considerable fraction of this variation is associated with effects
on signalling pathway activity phenotypes, as represented by PC1
(Fig. 2b). In line with this, our ID-seq antibody panel contained
several up- and downstream components of the pathways
involving some of the kinases targeted by groups of compounds
in the PKIS library. We conﬁrmed that these groups of inhibitors
indeed affect their expected read-outs, where upstream regulators
showed increased signals and downstream targets showed
decreased signals in our screen (Supplementary Fig. 15a-c). The
second largest PC identiﬁed in our analysis, PC2, strongly
correlates with proteins that are signiﬁcantly upregulated upon
differentiation, including the known marker proteins TGM1 and
NOTCH1 (Fig. 2b and Supplementary Fig. 1415, 27). Interestingly,
Cyclin B1, GAPDH and SMAD3 were also included in this cluster.
We conﬁrmed that changes of these molecular phenotypes
genuinely reﬂect keratinocyte differentiation, by forcing the cells
to differentiate using the EGFR inhibitor AG1478 for 48 h and
subjecting these samples to ID-seq (n= 6). Indeed, protein levels
of TGM1, NOTCH1, SMAD3, Cyclin B1 and GAPDH are
upregulated upon differentiation, corroborating the results of our
screen (Fig. 2c). To validate these screen results further, we
selected 18 probes that showed high PC2 scores from the PKIS
library for colony formation experiments, the gold standard
in vitro assay for epidermal stem cell proliferation (Supplementary
Fig. 16a, b28,) combined with IF measurement of differentiation
marker TGM1. Automated image analysis was used to quantify
colony number, colony size (and size distribution), as well as the
level of the differentiation marker TGM1 level per colony for each
probe (n= 3 replicates). Fifteen out of the eighteen tested probes
showed a signiﬁcant effect on at least one of the measured colony
phenotypes (Supplementary Fig. 16a, b). This indicates that high-
PC2 probes indeed affect epidermal cell colony-forming capacity
and authenticates the PC2 score as a bona ﬁde reﬂection of
differentiation.
Dynamic molecular processes in differentiated skin cells. We
gathered that the top and bottom 10% of PC2-ranked probes are
likely to distinguish the differentiating (high-PC2) and non-
differentiated (low-PC2) epidermal cell states. To determine
which molecular processes are different between these two cell
states, we identiﬁed the molecular phenotypes that display a
signiﬁcant increase or decrease (p < 0.01, 1% false discovery rate
(FDR), t-test) between cell populations with high PC2 vs. low
PC2. This revealed differential levels of the Wnt pathway (mea-
sured by Fzd3 and phosphorylated-LRP6), MAPK signalling
(phospho-p38, phospho-SRC, phospho-cFOS and phospho-
RSK), integrin-mediated adhesion (phospho-FAK) and the
mTOR pathway (phospho-mTOR and phospho-S6) (Fig. 3a and
Supplementary Fig. 17). Plotting the PC2 scores vs. the ID-seq
measurements of differentiation markers revealed that high-PC2
probes indeed display increased differentiation marker expression
(Fig. 3b), and have increased cell-cycle arrest markers (Fig. 3c).
Indeed, keratinocyte differentiation is associated with a G2/M
cell-cycle arrest in vivo and vitro29–31. Strikingly, all high-PC2
probes have a strong downregulation of the mTOR pathway
activity, suggesting a role for this pathway in epidermal biology
(Fig. 3d). To conﬁrm the suggestion of decreased mTOR signal-
ling in differentiating keratinocytes, we used an independent
approach to induce differentiation and performed RT-qPCR and
IF/in-cell western analysis of differentiating keratinocytes (Sup-
plementary Fig. 18). We induced differentiation by growing cells
at increasing cell density to induce a range of differentiation
levels. Subsequent IF measurements of TGM1, as well as RT-
qPCR analysis of TGM1 and Periplakin (PPL) conﬁrmed the
induction of differentiation of these samples (Supplementary
Fig. 18a, b). Consistent with the observation of inverse correlation
between mTOR signalling levels and differentiation markers in
the PKIS screen results, we observed an inverse correlation
between ribosomal S6 protein phosphorylation and cell density,
conﬁrming that decreased mTOR signalling is associated with
differentiation (Supplementary Fig. 18a). Moreover, we found
that mRNA expression levels of the mTOR co-factor RAPTOR,
but not of mTOR itself, decreased concordantly with the drop in
S6 phosphorylation levels, suggesting that decreased mTOR sig-
nalling activity is potentially caused by decreased RAPTOR gene
expression (Supplementary Fig. 18b). Of note, even though
decreased RAPTOR mRNA levels were associated with differ-
entiation, we found that siRNA-mediated silencing of RAPTOR
on its own was not sufﬁcient to cause cells to differentiate, as
assessed by RT-qPCR analysis of several key differentiation
markers (Supplementary Fig. 18c). Together, the ID-seq PKIS
screen uncovered relevant molecular phenotypes associated with
keratinocyte differentiation, including a decrease in mTOR sig-
nalling activity.
Identiﬁcation of kinases involved in skin stem cell renewal. We
reasoned that the inhibited kinases that strongly associated with
PC2 are likely involved in epidermal stem cell renewal, as their
inhibition leads to increased differentiation and cell-cycle arrest.
To determine which kinases are inhibited by probes with high
PC2 scores, we made use of available data on the biochemical
selectivity and potency of the PKIS compounds towards 225
individual kinases26. We applied outlier statistics to assign a set of
inhibitory probes to each of these 225 kinases (p < 0.01, Supple-
mentary Data 2). As indicated above, these probe sets show
expected effects on targeted or downstream signalling molecules
(Supplementary Fig. 15). Subsequent gene set enrichment analysis
(GSEA) identiﬁed 13 probe sets that were enriched (p < 0.01, 1%
FDR) in PC2 (i.e., probes inducing cell differentiation and/or cell-
cycle arrest) and of which the corresponding kinase is expressed
in keratinocytes (Fig. 4, Supplementary Figs. 19, 20). Our analysis
returned the EGFR as the top hit, reﬂecting its recognised
importance in epidermal stem cell renewal in vitro and in vivo.
The probes that inhibit the other kinases are distinct from those
inhibiting the EGFR, indicating that the identiﬁcation of these 12
kinases did not result from cross-reactivity of the probes towards
the EGFR (Supplementary Fig. 21a, b). Important to note is the
potential of each probe to inhibit more than one kinase (Sup-
plementary Fig. 21a), as the PKIS probe library was designed as a
platform for lead discovery and to provide chemical scaffolds for
further medicinal chemistry24–26. Additional to the EGFR, the list
of identiﬁed kinases included PRKD3 and FYN, two intracellular
kinases shown to impact epidermal biology32–36. Interestingly,
p70S6K is the downstream effector of the mTOR/RAPTOR
complex that phosphorylates the ribosomal S6 protein. The fact
our GSEA analysis identiﬁed this kinase matches our ﬁnding that
mTOR signalling is decreased upon epidermal differentiation
(Fig. 3c and Supplementary Fig. 18a-c). Moreover, immuno-
histochemical staining of human skin sections showed that the
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expression of the EGFR, RSK1 and PHKG1 is restricted to cells
residing in the epidermal stem cell niche, whereas NUAK1 is
expressed throughout the epidermis (Supplementary Fig. 22),
consistent with our ﬁndings that inhibition of these kinases
affects epidermal stem cell biology. Taken together, ID-seq
identiﬁed both known and previously unrecognised potential
kinase effectors of epidermal renewal across four major kinase
families (Fig. 2a, yellow nodes).
We investigated whether the information contained in the
ID-seq data set may be used to explore the underlying molecular
mechanism of the kinase inhibition. For each kinase set, we
calculated the mean effect on each of the measured molecular
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phenotypes. These kinase set-level molecular proﬁles were used
for both hierarchical clustering and PCA, separating these 13
enriched kinases into four distinct subgroups (Fig. 5a, b). The
EGFR and its immediate downstream kinases, LYN and FYN,
form a tight cluster, indicating that this grouping reﬂects
molecular mechanistic relationships. In turn, this predicts that
the kinases in the other subgroups may function through
mechanisms that are different and potentially independent from
the EGFR. If this was indeed the case, we would expect inhibition
of these kinases to result in distinctive effects on (subsets of) the
interrogated molecular phenotypes. We compared the inhibitory
effects (average model-derived estimate ± SEM) on the 20
molecular phenotypes distinguishing differentiated and renewing
epidermal cells (as deﬁned in Fig. 2c) for exemplars of these four
subgroups of kinases. Ranking these read-outs based on the effect
of EGFR inhibition and plotting the data of the other kinases in
the same order showed that their overall trends were conserved,
reﬂecting that these probe sets indeed affect epidermal cell
differentiation (Fig. 5c). Importantly, most of the kinases showed
statistically signiﬁcant deviations (p < 0.05, t-test) in discrete
subsets of molecular phenotypes compared to the EGFR,
indicating that they potentially function through distinct
mechanisms to regulate epidermal renewal (Fig. 5c). Together,
this analysis shows that ID-seq allows highly multiplexed
screening of hundreds of chemical probes, identifying kinases
involved in epidermal renewal and at the same time provides
information on the underlying molecular mechanism to categor-
ise the identiﬁed effector kinases.
Finally, as a ﬁrst step towards veriﬁcation of the importance of
the kinases representing these four subgroups in epidermal self-
renewal, we obtained inhibitors of the EGFR, RSK1-4, p70S6K,
NUAK1 and DYRK1A, independent from the PKIS library. These
chemical inhibitors were chosen as they were described to display
selectivity for their intended targets, although it is difﬁcult to fully
exclude any contribution from (lower afﬁnity) inhibition of
unintended targets kinases. We examined the effects of these
inhibitors on epidermal stem cell function using in vitro colony
formation assays (Fig. 6a, b and Supplementary Fig. 23). For this,
stem cells were ﬁrst allowed to adhere to the culture plate
containing a layer of feeder cells. Twenty-four hours after seeding,
the cultures were exposed to the kinase inhibitors in a broad
range of concentrations for the remainder of the culture period.
Subsequent automated imaging-based quantiﬁcation of the
resulting colonies revealed that inhibition of the EGFR, RSK1-4
and DYRK1A decreased the self-renewal capacity of the
epidermal stem cells (as determined by colony size) and
stimulated the expression of the late differentiation marker
TGM1. In contrast, p70S6K and NUAK1 inhibition resulted in
decreased renewal but did not increase TGM1 expression. These
results support a potential role for these kinases in epidermal
renewal, although further work will be required to fully
characterise and understand their contributions to this process.
Discussion
Cell-based phenotypic screens are frequently used in academia
and the pharmaceutical industry to identify leads for drug
development37, 38. However, obtaining insight into the molecular
mechanism of action of the selected compound can be time-
consuming and expensive38–40. We developed the ID-seq tech-
nology as an approach to facilitate high-throughput highly mul-
tiplexed molecular phenotyping. We showed that ID-seq could be
applied to large numbers of samples for precise and sensitive
protein measurements in ﬁxed cell populations. The dynamic
range of our counting strategy by sequencing is seemingly
broader than enzyme-linked immunosorbent assays and
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comparable to the other high-throughput screening assays such
as the AlphaScreen and the Luminex, respectively41, 42. These
assays measure proteins in solution, such as body ﬂuids and cell
extracts. In addition, the AlphaScreen technology requires pairs
of antibodies for each target, whereas ID-seq does not require cell
lysis, works on ﬁxed cells in multi-well plates and uses one
antibody per target. Therefore, we consider ID-seq as a novel
technology that is complementary to existing commercial
approaches.
We applied ID-seq to primary human epidermal keratino-
cytes in conjunction with the PKIS chemical probe library and
identiﬁed several kinases that are important for epidermal stem
cell function. The depth of measured molecular phenotypes in
our screen resulted in the identiﬁcation of the association
between decreased mTOR signalling pathway activity and epi-
dermal differentiation. This is in line with recent ﬁndings that
the mTOR pathway plays an important role in human kerati-
nocyte at the switch from proliferation to differentiation43.
Additionally, our ﬁndings serve as a valuable resource to identify
potential drugs that could lead to severe skin toxicity since many
targeted therapies in clinical trials are directed against
kinases44, 45. Thus, ID-seq allows high-throughput molecular
screening of kinase inhibitors and leads to meaningful insight in
skin biology.
The straightforward ID-seq workﬂow was designed to be
compatible with automation for applications in industry. This
scaling potential should enable in-depth analysis of mechanisms
of action for 100s, potentially 1000s, of compounds in a single
experiment. Beyond the kinase-based screening application pre-
sented here, the ID-seq technology can in principle be applied to
any cell system, any perturbation and with any validated
high-quality antibody, making it a ﬂexible solution for large-scale
high-dimensional phenotyping.
Methods
Cell culture and transfections. Keratinocytes (pooled foreskin strain KNP, Lonza)
were expanded as described31 supplemented with Rock inhibitor (Y-27632, 10 µM).
After expansion of the keratinocytes on feeders, the cells were grown for 1–3 days
on keratinocyte serum-free medium (KSFM) with supplements (bovine pituitary
extract (30 µg ml−1) and EGF (0.2 ng ml−1, Gibco) in a 96- or 384-well plate at
~10.000 cells/well. Before 48 h AG1478 treatment (10 µM), the cells were cultured
for 48 h in a 96-well plate. Before EGF stimulation, keratinocytes were grown for
3 days on KSFM with and 1 day without supplements. After starvation, cells were
stimulated with EGF (100 ng ml−1) for 5 min. For the PKIS screen, 10 000 cells
were seeded in a 384-well plate and grown for 24 h in KSFM with supplements,
followed by 24-h treatment with PKIS compounds (10 µM) or dimethylsulphoxide
(DMSO). siRNA nucleofections were performed with the Amaxa 96-well shuttle
system (Lonza). Keratinocytes were grown in KSFM to ~70% conﬂuency, harvested
and resuspended in cell line buffer SF. In all, 2 × 105 cells were used for each 20 μl
transfection (programme FF-113) with 1–2 μM siRNA duplexes. Please note that is
equivalent to 5–10 nM siRNA in conventional liposome-based transfections.
Transfected cells were incubated at ambient temperature for 5–10 min post
transfection and subsequently resuspended in pre-warmed KSFM. Silencer Select
siRNAs were used throughout this study (Ambion/Applied Biosystems).
Conjugation of antibodies to dsDNA. Antibodies and dsDNA were functionalised
and conjugated as described13. See Supplementary Data 1 for a list of antibodies. In
short, antibodies were functionalised with NHS-s-s-PEG4-tetrazine in a ratio of
1:10 in 50 mM borate-buffered saline (BBS), pH 8.4 (150 mM NaCl). Then, N3-
dsDNA was produced and functionalized with DBCO-PEG12-TCO (Jena
Bioscience). See Supplementary Data 3 for a list of oligo sequences. Finally, puriﬁed
functionalised antibodies were conjugated to puriﬁed functionalised DNA by 4-h
incubation at room temperature in borate-buffered saline, pH 8.4, in a ratio of 4:1
respectively. The reaction was quenched with an excess of 3,6-diphenyl tetrazine.
After pooling, the conjugates were incubated with ProtA/G beads in BBS overnight.
After thorough washes with phosphate-buffered saline (PBS), the conjugates were
eluted from the beads with 0.1 M citrate, pH 2.3, and immediately neutralised with
Tris-HCl, pH 8.8. Subsequently, a buffer exchange into PBS (pH 7.4) was per-
formed using two Zeba-spin desalting columns. The size of the eluted DNA was
checked on an agarose gel, conﬁrming that all unconjugated DNA was removed
using this puriﬁcation approach.
Antibody characterisation. Detailed information on the antibodies is summarised
in Supplementary Data 1. In brief, we selected antibodies suitable for IHC or IF
validated by manufacturer. The Developmental Studies Hybridoma Bank (DSHB)
antibodies were produced and puriﬁed as described13. We choose antibodies to
study a wide variety of biological processes as mentioned in the Results section. We
performed antibody-dilution series with all antibodies on our primary human
keratincoytes to show antibody-dependent signal via IF. Moreover, we coupled
antibodies to DNA barcodes as described in our conjugation and immuno-PCR
protocol13. These antibodies show antibody concentration-dependent signal via
immuno-PCR, indicating successful conjugation, release and detection of DNA
tags. Finally, we performed several modulation experiments to show speciﬁc
dynamics in our keratinocytes measured via the antibodies in IF, immuno-PCR
(Supplementary Data 1, Supplementary Figs. 6, 7 and 9) or ID-seq (Supplementary
Fig. 5 and Supplementary Fig. 8). Supplementary Fig. 5b shows protein levels
(measured via ID-seq) and mRNA levels measured via qPCR. qPCR analysis was
performed according to standard protocol (iQTM SYBR Green Supermix, CFX 96
machine). qPCR primers are show in Supplementary Table 1.
Immunostainings and release of DNA tags. Keratinocytes were ﬁxed with 4%
paraformaldehyde in PBS for 15 min at room temperature (RT), washed three
times with PBS and stored at 4 °C (up to 3–4 days before further use). Then, cells
were permeabilised and blocked for 30 min using 0.5× protein-free blocking buffer
(Thermo Fisher) in PBS with 0.1% Triton and 200 ng ml−1 single-strand Salmon
Sperm DNA (sssDNA). Blocking the cells and wells with sssDNA is crucial to
suppress background binding of the antibody–DNA conjugates13. Then, cells were
incubated with conjugated antibodies in the same buffer at 0.1 µg ml−1 antibody, at
4 °C overnight. After immunostaining with conjugates, the cells were thoroughly
washed with PBS (3× short, 3× 15 min and 3× short). Then, release buffer was
freshly prepared (10 mM dithiothreitol (DTT) in borate-buffered saline, pH 8.4).
Cells were incubated with 20–50 µl of release buffer depending on the plate type
and well size and incubated for 90 min at RT, with careful mixing (on a vortex)
every 30 min. Released DNA barcodes were collected and stored at −20 °C.
Sample barcoding and sequencing library preparation. To barcode the released
DNA tags from each cell population (see Supplementary Note 1 for sequence
design), a 25 µl PCR was performed per sample containing 8–15 µl sample with
released DNA tags, 0.2 mM dNTPs, 1 µl PFU polymerase, 1× PFU buffer (20 mM
Tris-HCl (pH 8.8), 2 mM MgSO4, 10 mM KCl, 10 mM (NH4)2SO4, 0.1% triton and
0.1 mgml−1 bovine serum albumin), spike-in DNA barcodes, forward primer
(AATGATACGGCGACCACCG, Biolegio) and a well-speciﬁc reverse primer
(Supplementary Data 3, Supplementary Fig. 1b). In a 96-well PCR machine (T100
Thermal Cycler, Biorad) the following programme was used: (1) 3 min at 95 °C; (2)
30 s at 95 °C; (3) 30 s at 60 or 54 °C; (4) 30 s at 72 °C; (5) repeat 2–4 nine times; (6)
5 min at 72 °C; and (7) ∞12 °C. Then, all well-speciﬁc labelled DNA barcodes from
one plate were pooled to one sample. This sample was puriﬁed using a PCR
puriﬁcation column (Qiagen) according to the manufacturer’s protocol. Samples
were eluted with 30 µl nuclease-free water. To remove any residual primers,
samples were treated with Exonuclease I in 1× PFU buffer for 30 min at 37 °C.
After inactivation for 20 min at 80 °C, another 25 µl PCR reaction was prepared
with 15–17 µl sample, 0.2 mM dNTPs, ×1 µl PFU polymerase, 1 × PFU buffer,
forward primer (AATGATACGGCGACCACCG, Biolegio) and a sample-speciﬁc
reverse primer with Illumina index barcode and adapter sequence (Supplementary
Data 3, Supplementary Fig. 1d). The same programme as PCR reaction (I) was
used, and reactions were puriﬁed over a PCR puriﬁcation column (Qiagen). All
PCR reactions were then incubated for 45 min with 1 µl Exonuclease I to remove
residual primers. The PKIS screen samples were further size-selected using size
selection columns (Zymo, according to the manufacturer’s protocol) for fragments
> 150 bp. Finally, all samples were puriﬁed over PCR puriﬁcation mini-elute col-
umn (Qiagen) and eluted in 10 µl elution buffer. Final sequencing samples were
run on a 2% agarose gel (0.5× TBE) with 10× SYBR Green I (Life Technologies)
and scanned on a Typhoon Trio+ machine (GE Healthcare), or analysed with the
2100 Bioanalyzer (Agilent) to conﬁrm the size of the DNA fragments (expected size
around 185 bp).
ID-seq data analysis. Sequence data from the NextSeq500 (Illumina) were
demultiplexed using bcl2fastq software (Illumina). The quality of the sequencing
data was evaluated using a FastQC tool (version 0.11.4 and 0.11.5, Babraham
Bioinformatics). Then, all reads were processed using our dedicated R-package
(IDSeq, Supplementary Note 2). In short, the sequencing reads were split using a
common anchor sequence identifying the position of the UMI sequence, barcode 1
(antibody-speciﬁc) and barcode 2 (well-speciﬁc) sequence. After removing all
duplicate reads, the number of UMI sequences were counted per barcode 1 and 2.
Finally, barcode 1 and barcode 2 sequences were matched to the corresponding
antibody and well information.
Using R-package DESeq246, we calculated normalisation factors (estimated size
factor) to account for differences in sequencing depth per sample. Using lme4, we
analysed the effect of a speciﬁc condition using a linear mixed effect model
(Supplementary Note 3).
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For each antibody in the PKIS screen the effect and signiﬁcance of each
treatment were determined as described in Supplementary Note 3. Then, the
‘signed p-value’ was derived from the sign of the model estimate (positive/negative)
and the p-value. This signed p-value was used as input for the PCAs (Fig. 2b and
Supplementary Fig. 15). To calculate effects of probe sets per molecular phenotype,
the mean model estimate was calculated. These means were used for subsequent
PCA analysis and ‘molecular phenotype proﬁles’ described in Fig. 5.
Immuno-PCR experiments. The immuno-PCR experiments were performed as
described previously in our paper on antibody–DNA conjugates13. In short, each
antibody was conjugated to dsDNA, and used in an immunostaining as described.
DNA was released using 10 mM DTT in BBS, pH 8.4, and measured by quanti-
tative PCR using iQTM SYBR Green Supermix on CFX 96 machine. The 2−Ct
values were used to calculate the mean signal and standard deviation from four
biological replicates. The Pearson correlation between these immuno-PCR and the
multiplexed ID-seq signal was calculated using the mean.
Proteomics. Cells were harvested, washed, snap-frozen and stored at −80 °C until
lysis and mass spectrometry (MS) analysis. Induction of differentiation was vali-
dated by qPCR (data not shown) before lysis. Cells were lysed using lysis buffer (4%
SDS, 100 mM Tris-HCl (pH 7.6) and 100 mM DTT) and by boiling for 3 min at 95
°C. DNA was sheared using sonication, 5 cycles: 30 s ON and 30 s OFF (high). The
samples were centrifuged for 5 min at 16 000 × g, 4 °C and the supernatant was
taken for protein quantiﬁcation with the PierceTM BCA Protein Assay Kit (Thermo
Scientiﬁc).
For the generation of tryptic peptides, we applied ﬁlter-aided sample
preparation47. To be able to absolutely quantify the proteins in the samples we used
a standard range of proteins (UPS2-1SET, Sigma), which we spiked into one of the
samples (3.3 µg in sample equivalent to 100 000 cells)48. To obtain deep-proteomes,
samples were fractionated using strong anion exchange, collecting fractions of the
ﬂow through and elutions at pH 11, 8, 5 and 2 of Britton& Robinson buffer.
Samples were desalted and concentrated using C18 stage tips.
The peptide samples were separated on an Easy nLC 1000 (Thermo Scientiﬁc)
connected online to a Thermo scientiﬁc Orbitrap Fusion Tribrid mass
spectrometer. A 240 min acetonitrile gradient (5–23%, 8–27%, 9–30%, 11–32% and
14–32% for FT, pH 11, 8, 5 and 2, respectively) was applied to the ﬁve fractions. MS
and MS/MS spectra were recorded in a Top speed modus with a run cycle of 3 s.
MS/MS spectra were recorded in the Ion trap using higher-energy collision
dissociation fragmentation. To analyse the raw MS data we used MaxQuant
(version 1.5.1.0, database: Uniprot_201512/HUMAN)49 with default setting and
the match between runs and iBAQ algorithms enabled. We ﬁltered out reverse hits
and imputed missing values using Perseus (default settings, MaxQuant software
package).
CEL-seq2 mRNA quantiﬁcation. mRNA sequencing was performed according to
the CEL-seq2 protocol50 with adaptations. Reverse transcription was performed in
2 µl reactions overlaid with 7 µl Vapor-Lock (Qiagen) using Maxima H minus
reverse transcriptase (Thermo Fisher) and 100 pg puriﬁed RNA per sample. Primer
sequences were adapted to allow sequencing of 63 nucleotides of mRNA in read 1
and 14 nucleotides in read 2, comprising the sample barcode and UMI. Reverse
transcription primer: 5′GCCGGTAATACGACTCACTATAGGGGTTCAGACGT
GTGCTCTTCCGATCTNNNNNNNN[6ntsample-barcode]TTTTTTTTTTTTTT
TTTTTTTTTTV3′, random-octamer-primer for reverse transcription of ampliﬁed
RNA: 5′CACGACGCTCTTCCGATCTNNNNNNNN3′, libraryPCRPrimers:
5′AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCT
TCCGATCT3′ and 5′CAAGCAGAAGACGGCATACGAGAT[6ntindex]GTGAC
TGGAGTTCAGACGTGTG-CTCTTCCGATC3′.
Sequencing was performed using the NextSeq500 from Illumina.
Colony formation assay. In six-well plate, 200 000 feeder (J2-3T3) cells were
seeded in Dulbecco’s modiﬁed Eagle’s medium (DMEM; with 10% bovine serum
(BS) and 1% pen/strep). After 1 day, feeder cells were inactivated by 3-h treatment
with mitomycin C. After thorough washes with DMEM, 1000 keratinocytes were
seeded into each well. The following day, treatment was started (day 0) by
refreshing medium and addition of the indicated concentration of compound, or
DMSO as a vehicle control. Cells were grown in the presence of compounds for 8
more days, and the medium was refreshed on days 2 and 5. Rocki was present until
day 2 of the treatment. Cells were ﬁxed, stained with TGM1-speciﬁc antibodies and
scanned as described before27. Raw images from the LiCor Odessey system were
processed with CC Photoshop and CellProﬁler with consistent settings. Data
obtained via automatic counting and imaging analysis via CellProﬁler were ana-
lysed and visualised in the R programming language.
Code availability. R-package IDseq (version 0.1.0) is available from https://github.
com/jessievb/IDseq. Colony-forming assay analysis scripts (Cell-proﬁler and
R-script) are available from https://github.com/jessievb/automated_CFA.
Data availability. Used antibodies and oligo sequences are available as Supple-
mentary Data 1 and Supplementary Data 3, respectively. Sequencing data and
processed data from ID-seq experiments are available through GEO43 Ser-
ies accession number GSE100135. CEL-seq2 data to identify highly expressed
kinases (Supplementary Fig. 19) are available upon reasonable request. Images-
from Supplementary Fig. 22 were obtained from Human Protein Atlas (Version
16.1).
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